Physician profile
Hetty Chung
NPI 1275504714
$2,151.96
in general payments reported to CMS, 2019-2025
25 companies · $27.79 in 2025
The $27.79 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $371 · 2021: $198 · 2022: $417 · 2023: $245 · 2024: $16.34 · 2025: $27.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.34 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.97 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Celularity INC. | $300.00 | 2022 | |
| Exeltis, USA INC. | $131.44 | 2019-2020 | |
| Lupin INC. | $122.63 | 2019-2020 | |
| Roche Diagnostics Corporation | $107.03 | 2019 | |
| Coopersurgical, INC. | $105.51 | 2019-2021 | |
| Therapeuticsmd, INC. | $98.61 | 2019-2020 | |
| Organon LLC | $91.40 | 2022-2023 | Nexplanon |
| Hologic Sales and Service, LLC | $87.83 | 2021-2023 | Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $78.82 | 2023-2025 | |
| Amag Pharmaceuticals, INC. | $71.81 | 2019 | |
| Avion Pharmaceuticals | $59.19 | 2020-2021 | |
| Allergan, INC. | $52.98 | 2019 | |
| Millicent US INC | $51.74 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $48.20 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $38.89 | 2020-2021 | |
| Pfizer INC. | $33.98 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.19 | 2023 | |
| Myovant Sciences INC. | $24.69 | 2021 | |
| Zimmer Biomet Holdings, INC. | $19.81 | 2019 | |
| Duchesnay USA Incorporated | $19.09 | 2019 | |
| Astellas Pharma US INC | $19.03 | 2023 | Veozah |
| Smith+Nephew, INC. | $16.74 | 2020 | |
| Biogen, INC. | $14.70 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetty Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.